Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C

D. H. Van Thiel, L. Friedlander, P. Malloy, H. I. Wright, Ahmet Gurakar, S. Fagiuoli, W. Irish

Research output: Contribution to journalArticle

Abstract

Backgound/Aims: This study was performed to identify response predictors for Interferon therapy given to patients with chronic hepatitis C. Materials and Methods: The biochemical measures of liver injury that characterize viral hepatitis due to hepatitis C were followed prospectively in 84 individuals treated with α-Interferon. In addition, the liver histology and the hepatic iron content of these same individuals, prior to the initiation of Interferon therapy, were determined. Results: Patients not responding to the interferon therapy showed an increase in liver iron content from an average of 337 ug/g wet weight. In responder to a value of 1075 μg/g wet weight in non responders. γ-glutamyl transpeptidase levels in responders were significantly lower than in partial or non-responders. Conclusions: Both the hepatic iron content of the liver and the γ-glutamyl transpeptidase value prior to treatment were able to predict a clinical response to Interferon therapy. More importantly, the γ-glutamyl transpeptidase level measured in serum could be used to monitor the IFN response during treatment and was found to predict clinical exacerbations of hepatitis following withdrawal of interferon therapy.

Original languageEnglish (US)
Pages (from-to)888-892
Number of pages5
JournalHepato-Gastroenterology
Volume42
Issue number6
StatePublished - 1995
Externally publishedYes

Fingerprint

gamma-Glutamyltransferase
Hepatitis C
Interferons
Liver
Iron
Therapeutics
Hepatitis
Weights and Measures
Chronic Hepatitis C
Histology
Wounds and Injuries
Serum

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Van Thiel, D. H., Friedlander, L., Malloy, P., Wright, H. I., Gurakar, A., Fagiuoli, S., & Irish, W. (1995). Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C. Hepato-Gastroenterology, 42(6), 888-892.

Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C. / Van Thiel, D. H.; Friedlander, L.; Malloy, P.; Wright, H. I.; Gurakar, Ahmet; Fagiuoli, S.; Irish, W.

In: Hepato-Gastroenterology, Vol. 42, No. 6, 1995, p. 888-892.

Research output: Contribution to journalArticle

Van Thiel, DH, Friedlander, L, Malloy, P, Wright, HI, Gurakar, A, Fagiuoli, S & Irish, W 1995, 'Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C', Hepato-Gastroenterology, vol. 42, no. 6, pp. 888-892.
Van Thiel DH, Friedlander L, Malloy P, Wright HI, Gurakar A, Fagiuoli S et al. Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C. Hepato-Gastroenterology. 1995;42(6):888-892.
Van Thiel, D. H. ; Friedlander, L. ; Malloy, P. ; Wright, H. I. ; Gurakar, Ahmet ; Fagiuoli, S. ; Irish, W. / Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C. In: Hepato-Gastroenterology. 1995 ; Vol. 42, No. 6. pp. 888-892.
@article{d318d8243a814e509d2aab43fbcbffce,
title = "Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C",
abstract = "Backgound/Aims: This study was performed to identify response predictors for Interferon therapy given to patients with chronic hepatitis C. Materials and Methods: The biochemical measures of liver injury that characterize viral hepatitis due to hepatitis C were followed prospectively in 84 individuals treated with α-Interferon. In addition, the liver histology and the hepatic iron content of these same individuals, prior to the initiation of Interferon therapy, were determined. Results: Patients not responding to the interferon therapy showed an increase in liver iron content from an average of 337 ug/g wet weight. In responder to a value of 1075 μg/g wet weight in non responders. γ-glutamyl transpeptidase levels in responders were significantly lower than in partial or non-responders. Conclusions: Both the hepatic iron content of the liver and the γ-glutamyl transpeptidase value prior to treatment were able to predict a clinical response to Interferon therapy. More importantly, the γ-glutamyl transpeptidase level measured in serum could be used to monitor the IFN response during treatment and was found to predict clinical exacerbations of hepatitis following withdrawal of interferon therapy.",
author = "{Van Thiel}, {D. H.} and L. Friedlander and P. Malloy and Wright, {H. I.} and Ahmet Gurakar and S. Fagiuoli and W. Irish",
year = "1995",
language = "English (US)",
volume = "42",
pages = "888--892",
journal = "Acta hepato-splenologica",
issn = "0172-6390",
publisher = "H.G.E. Update Medical Publishing Ltd.",
number = "6",

}

TY - JOUR

T1 - Γ-glutamyl transpeptidase as a response predictor when using α-interferon to treat hepatitis C

AU - Van Thiel, D. H.

AU - Friedlander, L.

AU - Malloy, P.

AU - Wright, H. I.

AU - Gurakar, Ahmet

AU - Fagiuoli, S.

AU - Irish, W.

PY - 1995

Y1 - 1995

N2 - Backgound/Aims: This study was performed to identify response predictors for Interferon therapy given to patients with chronic hepatitis C. Materials and Methods: The biochemical measures of liver injury that characterize viral hepatitis due to hepatitis C were followed prospectively in 84 individuals treated with α-Interferon. In addition, the liver histology and the hepatic iron content of these same individuals, prior to the initiation of Interferon therapy, were determined. Results: Patients not responding to the interferon therapy showed an increase in liver iron content from an average of 337 ug/g wet weight. In responder to a value of 1075 μg/g wet weight in non responders. γ-glutamyl transpeptidase levels in responders were significantly lower than in partial or non-responders. Conclusions: Both the hepatic iron content of the liver and the γ-glutamyl transpeptidase value prior to treatment were able to predict a clinical response to Interferon therapy. More importantly, the γ-glutamyl transpeptidase level measured in serum could be used to monitor the IFN response during treatment and was found to predict clinical exacerbations of hepatitis following withdrawal of interferon therapy.

AB - Backgound/Aims: This study was performed to identify response predictors for Interferon therapy given to patients with chronic hepatitis C. Materials and Methods: The biochemical measures of liver injury that characterize viral hepatitis due to hepatitis C were followed prospectively in 84 individuals treated with α-Interferon. In addition, the liver histology and the hepatic iron content of these same individuals, prior to the initiation of Interferon therapy, were determined. Results: Patients not responding to the interferon therapy showed an increase in liver iron content from an average of 337 ug/g wet weight. In responder to a value of 1075 μg/g wet weight in non responders. γ-glutamyl transpeptidase levels in responders were significantly lower than in partial or non-responders. Conclusions: Both the hepatic iron content of the liver and the γ-glutamyl transpeptidase value prior to treatment were able to predict a clinical response to Interferon therapy. More importantly, the γ-glutamyl transpeptidase level measured in serum could be used to monitor the IFN response during treatment and was found to predict clinical exacerbations of hepatitis following withdrawal of interferon therapy.

UR - http://www.scopus.com/inward/record.url?scp=0029417301&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029417301&partnerID=8YFLogxK

M3 - Article

C2 - 8847041

AN - SCOPUS:0029417301

VL - 42

SP - 888

EP - 892

JO - Acta hepato-splenologica

JF - Acta hepato-splenologica

SN - 0172-6390

IS - 6

ER -